Immunovant, Inc.
IMVTNASDAQHealthcare● Active
$30.97
$-0.14(-0.45%)
Market Cap$6.4B
P/E Ratio—
52W High$36.285
52W Low$14.32
Immunovant, Inc. (IMVT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMVT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 20, 2026EPS Actual
-$0.73
Est. -$0.60 · -21.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 20, 2026
After Market Close
▼ Miss EPS
IMVT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.60 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 20, 2026 | -$0.60 | -$0.73 | -21.7% | — | — | — |
| ▲ Q1 FY2026 | Feb 6, 2026 | -$0.72 | -$0.61 | +15.3% | — | $0.01B | — |
| ▼ Q4 FY2025 | Nov 10, 2025 | -$0.72 | -$0.73 | -1.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 11, 2025 | -$0.69 | -$0.60 | +13.0% | — | — | — |
| ▲ Q2 FY2025 | May 29, 2025 | -$0.71 | -$0.64 | +10.3% | — | — | — |
| ▼ Q1 FY2025 | Feb 6, 2025 | -$0.73 | -$0.76 | -4.1% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.61 | -$0.74 | -21.3% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 20, 2026Miss
EPS Actual
-$0.73
EPS Est.
-$0.60
EPS Surpr.
-21.7%
Revenue
—
Q1 FY2026
Feb 6, 2026Beat
EPS Actual
-$0.61
EPS Est.
-$0.72
EPS Surpr.
+15.3%
Revenue
—
Q4 FY2025
Nov 10, 2025Miss
EPS Actual
-$0.73
EPS Est.
-$0.72
EPS Surpr.
-1.4%
Revenue
—
Q3 FY2025
Aug 11, 2025Beat
EPS Actual
-$0.60
EPS Est.
-$0.69
EPS Surpr.
+13.0%
Revenue
—
Q2 FY2025
May 29, 2025Beat
EPS Actual
-$0.64
EPS Est.
-$0.71
EPS Surpr.
+10.3%
Revenue
—
Q1 FY2025
Feb 6, 2025Miss
EPS Actual
-$0.76
EPS Est.
-$0.73
EPS Surpr.
-4.1%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.74
EPS Est.
-$0.61
EPS Surpr.
-21.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q4 FY2028 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Q3 FY2028 | $-0.58 | $-0.58 | $-0.58 | 1 |
| Q2 FY2028 | $-0.59 | $-0.59 | $-0.59 | 1 |
| Q1 FY2028 | $-0.61 | $-0.61 | $-0.61 | 1 |
| Q4 FY2027 | $-0.59 | $-0.59 | $-0.59 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 20, 2026 | -21.7% | $26.29 | $35.56 | +35.26% |
| ▲ Q1 FY2026 | Feb 6, 2026 | +15.3% | $24.06 | $27.05 | +12.43% |
| ▼ Q4 FY2025 | Nov 10, 2025 | -1.4% | $23.35 | $23.37 | +0.09% |
| ▲ Q3 FY2025 | Aug 11, 2025 | +13.0% | $15.46 | $14.76 | -4.53% |
| ▲ Q2 FY2025 | May 29, 2025 | +10.3% | $14.10 | $14.89 | +5.60% |
| ▼ Q1 FY2025 | Feb 6, 2025 | -4.1% | $22.51 | $20.36 | -9.55% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -21.3% | $31.42 | $29.93 | -4.74% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -13.2% | $26.71 | $27.85 | +4.27% |
Q2 FY2026+35.26%
Report Date
May 20, 2026
EPS Beat/Miss
-21.7%
Price Before
$26.29
Price After
$35.56
Q1 FY2026+12.43%
Report Date
Feb 6, 2026
EPS Beat/Miss
+15.3%
Price Before
$24.06
Price After
$27.05
Q4 FY2025+0.09%
Report Date
Nov 10, 2025
EPS Beat/Miss
-1.4%
Price Before
$23.35
Price After
$23.37
Q3 FY2025-4.53%
Report Date
Aug 11, 2025
EPS Beat/Miss
+13.0%
Price Before
$15.46
Price After
$14.76
Q2 FY2025+5.60%
Report Date
May 29, 2025
EPS Beat/Miss
+10.3%
Price Before
$14.10
Price After
$14.89
Q1 FY2025-9.55%
Report Date
Feb 6, 2025
EPS Beat/Miss
-4.1%
Price Before
$22.51
Price After
$20.36
Q4 FY2024-4.74%
Report Date
Nov 7, 2024
EPS Beat/Miss
-21.3%
Price Before
$31.42
Price After
$29.93
Q3 FY2024+4.27%
Report Date
Aug 6, 2024
EPS Beat/Miss
-13.2%
Price Before
$26.71
Price After
$27.85
Avg Beat Reaction+4.50%
Avg Miss Reaction+5.07%
Beat Rate3 / 8 quarters
Largest Move+35.26% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMVT ends December
Immunovant, Inc. (IMVT) most recently reported earnings on May 20, 2026 for Q2 FY2026, posting EPS of $-0.73 — missing the analyst consensus of $-0.60 by -21.7%. The next IMVT earnings date is expected around September 1, 2026.
Each quarter, investors track IMVT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMVT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMVT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMVT earnings · 5 questionsImmunovant, Inc.'s next earnings report is expected around September 1, 2026. IMVT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMVT historically reports after market close (AMC).
IMVT earnings datewhen is IMVT earningsIMVT next earnings datewhen does IMVT report earningsIMVT earnings calendar
▸ Source: FMP · Immunovant, Inc. SEC filings · US GAAP · Immunovant, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026